Taken together, our observations of high proportions of CD4+CD25+FoxP3+ Tregs in tumors and CD8+ T cell recruitment blockage strongly support the possibility that these Tregs may inhibit local antitumor immunity at the tumor site. The gene discussed is CD4; the disease is neoplasm.